Yanfeng Xi

2.2k total citations
78 papers, 713 citations indexed

About

Yanfeng Xi is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Yanfeng Xi has authored 78 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 28 papers in Molecular Biology and 21 papers in Cancer Research. Recurrent topics in Yanfeng Xi's work include Cancer Immunotherapy and Biomarkers (10 papers), Cancer-related molecular mechanisms research (9 papers) and Immune Cell Function and Interaction (9 papers). Yanfeng Xi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Cancer-related molecular mechanisms research (9 papers) and Immune Cell Function and Interaction (9 papers). Yanfeng Xi collaborates with scholars based in China, United States and Sweden. Yanfeng Xi's co-authors include Jing Xu, Kun Yang, Jing Li, Lijun Yang, Hong Li, Gao‐Jun Teng, He Wu, Ji Qi, Zan Lin-sen and Yuwen Song and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Yanfeng Xi

70 papers receiving 709 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yanfeng Xi China 16 276 269 185 133 114 78 713
Xiaolong Wu China 14 241 0.9× 317 1.2× 231 1.2× 87 0.7× 127 1.1× 70 723
Dong Lin China 14 186 0.7× 263 1.0× 195 1.1× 130 1.0× 77 0.7× 67 714
Qiang Zuo China 13 315 1.1× 417 1.6× 200 1.1× 79 0.6× 100 0.9× 39 805
Xiao‐Peng Tian China 16 220 0.8× 287 1.1× 171 0.9× 101 0.8× 127 1.1× 41 654
Hilal Oğuz Türkiye 17 341 1.2× 346 1.3× 160 0.9× 170 1.3× 35 0.3× 44 780
Can Gong United States 11 321 1.2× 386 1.4× 175 0.9× 173 1.3× 123 1.1× 17 875
Matthew J. Goldstein United States 14 318 1.2× 212 0.8× 103 0.6× 421 3.2× 198 1.7× 29 975
Karolina Przybyłowska Poland 17 241 0.9× 379 1.4× 303 1.6× 88 0.7× 103 0.9× 48 828
Qi Wan China 15 118 0.4× 401 1.5× 199 1.1× 96 0.7× 40 0.4× 58 751
Şahsine Tolunay Türkiye 18 226 0.8× 310 1.2× 293 1.6× 37 0.3× 124 1.1× 77 870

Countries citing papers authored by Yanfeng Xi

Since Specialization
Citations

This map shows the geographic impact of Yanfeng Xi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanfeng Xi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanfeng Xi more than expected).

Fields of papers citing papers by Yanfeng Xi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanfeng Xi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanfeng Xi. The network helps show where Yanfeng Xi may publish in the future.

Co-authorship network of co-authors of Yanfeng Xi

This figure shows the co-authorship network connecting the top 25 collaborators of Yanfeng Xi. A scholar is included among the top collaborators of Yanfeng Xi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanfeng Xi. Yanfeng Xi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Zhiqiang, et al.. (2025). Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study. Frontiers in Oncology. 14. 1494384–1494384. 1 indexed citations
2.
Pan, Hong, Yanfeng Xi, Jin Ding, et al.. (2025). Effects of moxibustion at different temperature on wound healing and apoptosis in rats with pressure ulcer based on PI3K/AKT/mTOR signal pathway. World Journal of Acupuncture - Moxibustion. 35(2). 125–134.
3.
Chen, Fengxin, et al.. (2024). Exploring the expression and clinical significance of the miR-140-3p-HOXA9 axis in colorectal cancer. Journal of Cancer Research and Clinical Oncology. 150(2). 47–47.
4.
Dai, Jie, Fanshuang Zhang, Yanfeng Xi, et al.. (2024). Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications. Cancer Research Communications. 4(5). 1351–1362. 2 indexed citations
5.
Xi, Yanfeng, et al.. (2023). Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology. 149(11). 8573–8580. 2 indexed citations
6.
Wang, Xiaoyuan, Zixian Liu, Qianqian Duan, et al.. (2023). 3D bioprinting of in vitro porous hepatoma models: establishment, evaluation, and anticancer drug testing. Bio-Design and Manufacturing. 7(2). 137–152. 8 indexed citations
7.
Du, Yu, Xiaohui Wang, Yuanfang Zhai, et al.. (2023). TSTA3 overexpression promotes malignant characteristics in LUSC by regulating LAMP2-mediated autophagy and tumor microenvironment. Cancer Cell International. 23(1). 285–285. 3 indexed citations
8.
Xue, Xuemin, Changyuan Guo, Yun Ling, et al.. (2023). Comparing digital and glass slide methods for determining the HER2-low and negative categories in breast cancer.. Journal of Clinical Oncology. 41(16_suppl). e13042–e13042.
9.
Li, Jing, et al.. (2023). Value of Methylation Status of RPRM, SDC2, and TCF4 Genes in Plasma for Gastric Adenocarcinoma Screening. International Journal of General Medicine. Volume 16. 673–681. 3 indexed citations
10.
11.
Ma, Haixia, et al.. (2022). Subclassifying triple-negative breast cancers and its potential clinical utility. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 481(1). 13–21. 8 indexed citations
12.
Hu, Xiaoqin, Yanfeng Xi, Zhenjun Zhang, et al.. (2022). Polymorphisms of adiponectin gene and gene–lipid interaction with hypertension risk in Chinese coal miners: A matched case-control study. PLoS ONE. 17(9). e0268984–e0268984. 4 indexed citations
13.
Xi, Yanfeng, Yunhan Ma, Chenxi Wang, et al.. (2021). Vitamin D3 combined with antibody agents suppresses alloreactive memory T-cell responses to induce heart allograft long-term survival. Transplant Immunology. 66. 101374–101374. 1 indexed citations
14.
Jin, Hui, et al.. (2020). The miR-582/CD1B Axis Is Involved in Regulation of Dendritic Cells and Is Associated with Clinical Outcomes in Advanced Lung Adenocarcinoma. BioMed Research International. 2020(1). 4360930–4360930. 10 indexed citations
15.
Xi, Yanfeng, Chen Xu, Yiqiang Liu, et al.. (2020). The age variation of HER2 immunohistochemistry positive rate in biopsy specimens of gastric cancer. Pathology - Research and Practice. 216(4). 152882–152882. 3 indexed citations
16.
17.
Yang, Qin, Zhi‐Yong Wu, Suan Sun, et al.. (2018). PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins. Journal of Immunology Research. 2018. 1–10. 14 indexed citations
18.
Li, Hongwei, Weili Wang, Jianzhong Cao, et al.. (2017). Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations. Journal of Neuro-Oncology. 133(1). 129–135. 4 indexed citations
19.
Gao, Ning, Yanfeng Xi, Yuehua Wang, Yaling Li, & Jianghong Guo. (2015). Epidermal growth factor receptor, KRAS and BRAF gene mutations and their correlation with clinicopathological characteristics in non-small-cell lung cancer. 27(8). 551–554. 1 indexed citations
20.
Lin, Yingying, Helong Dai, Guoliang Yan, et al.. (2011). Arsenic trioxide is a novel agent for combination therapy to prolong heart allograft survival in allo-primed T cells transferred mice. Transplant Immunology. 25(4). 194–201. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaolong Wu Breakdown of academic impact, for papers by Dong Lin Breakdown of academic impact, for papers by Qiang Zuo Breakdown of academic impact, for papers by Xiao‐Peng Tian Breakdown of academic impact, for papers by Hilal Oğuz Breakdown of academic impact, for papers by Can Gong Breakdown of academic impact, for papers by Matthew J. Goldstein Breakdown of academic impact, for papers by Karolina Przybyłowska Breakdown of academic impact, for papers by Qi Wan Breakdown of academic impact, for papers by Şahsine Tolunay
Rankless by CCL
2026